We are live on ! Find out more
TRIB

Trinity Biotech

19 hedge funds and large institutions have $5.95M invested in Trinity Biotech in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

130% more capital invested

Capital invested by funds: $2.59M → $5.95M (+$3.37M)

0.76% more ownership

Funds ownership: 0.79%1.55% (+0.76%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

27% less funds holding

Funds holding: 2619 (-7)

50% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 12

86% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 7

Holders
19
Holders Change
-7
Holders Change %
-26.92%
% of All Funds
0.27%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
6
Increased
1
Reduced
7
Closed
12
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
RWMG
26
Redwood Wealth Management Group
New Jersey
-$6.07K -2,830 Closed
DAS
27
Dynamic Advisor Solutions
Arizona
-$5.3K -2,000 Closed
WN
28
Williams & Novak
California
-$4.29K -2,000 Closed
US Bancorp
29
US Bancorp
Minnesota
-$417 -194 Closed
Citigroup
30
Citigroup
New York
-$2 -1 Closed

TRIB Hedge Fund Activity: Q1 2024 in Review

19 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q1 2024, worth a combined $5.95M — up 130% from $2.59M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of TRIB and 6 opened new positions — a net loss of 6 holders — while 7 trimmed existing stakes and 1 added.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $4.22M. The largest seller was Stonehill Capital Management, cutting an estimated $127K.

  • 19 institutional investors held Trinity Biotech (TRIB) as of Q1 2024, down from 26 in Q4 2023.
  • Funds reported $5.95M of Trinity Biotech stock for Q1 2024, up 130% quarter-over-quarter.
  • 6 funds opened new Trinity Biotech positions in Q1 2024 and 12 closed out, a net change of -6 holders.
  • The largest Trinity Biotech buyer in Q1 2024 was Perceptive Advisors, an estimated $4.22M added.
  • The largest Trinity Biotech seller in Q1 2024 was Stonehill Capital Management, an estimated $127K sold.

Based on aggregated 13F filings for Q1 2024.